Search Results

Business

XOMA Declares Quarterly Preferred Stock Dividends - June 20, 2024

XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

June 20, 2024

·

3 min read

Deals

XOMA Declares Quarterly Preferred Stock Dividends - March 21, 2024

XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

March 21, 2024

·

3 min read

Business

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Corporation, the biotech royalty aggregator, reported its first quarter 2024 financial results and highlighted recent activities.

May 9, 2024

·

14 min read

Biotech Bay

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

XOMA Corporation, the biotech royalty aggregator, announced it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority Review Voucher for $108 million to an undisclosed buyer.

June 12, 2024

·

4 min read

Biotech Bay

XOMA to Present at Upcoming Investor Conferences in March

XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor conferences.

February 28, 2024

·

1 min read

Biotech Bay

XOMA Corporation Announces Closing of Tender Offer

XOMA Corporation announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc.

April 3, 2024

·

5 min read

Biotech Bay

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

XOMA Corporation, the biotech royalty aggregator, announced that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY.

May 14, 2024

·

1 min read

Deals

XOMA Announces Stock Repurchase Program of up to $50 Million

XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized XOMA’s first stock repurchase program, which permits the Company to purchase up to $50 million of XOMA’s common stock through January 2027.

January 2, 2024

·

4 min read

Business

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its fourth quarter and full year 2023 financial results and highlighted portfolio activities expected to drive long-term shareholder value.

March 8, 2024

·

14 min read

Biotech Bay

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

XOMA Corporation announced it has acquired an economic interest in three women’s health assets - XACIATO™ vaginal gel 2%, Ovaprene®, and Sildenafil Cream, 3.6% - from Daré Bioscience, Inc., for an upfront payment of $22 million.

April 30, 2024

·

7 min read